Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXRNASDAQ:ECORNASDAQ:MODDNASDAQ:PAVM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$7.74-3.3%$7.73$6.55▼$10.00$37.44M-0.216,232 shs1,563 shsECORelectroCore$4.97-1.0%$6.21$4.47▼$19.49$36.88M0.9292,973 shs77,317 shsMODDModular Medical$0.85+2.3%$0.97$0.68▼$2.65$46.26M0.33207,779 shs55,861 shsPAVMPAVmed$0.65-0.5%$0.71$0.55▼$1.90$11.06M1.11126,040 shs124,510 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor0.00%+1.04%-0.39%+6.91%-19.29%ECORelectroCore0.00%-7.96%-34.17%-71.87%-28.97%MODDModular Medical0.00%-12.08%-8.89%-21.76%-45.33%PAVMPAVmed0.00%-0.34%-14.30%-18.31%-64.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxor3.784 of 5 stars3.55.00.00.00.63.30.0ECORelectroCore2.1776 of 5 stars3.53.00.00.00.62.50.6MODDModular Medical0.8573 of 5 stars0.05.00.00.00.03.30.0PAVMPAVmed3.575 of 5 stars3.54.00.04.30.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00223.00% UpsideECORelectroCore 3.00Buy$25.50413.08% UpsideMODDModular Medical 0.00N/AN/AN/APAVMPAVmed 3.00Buy$19.502,914.84% UpsideCurrent Analyst Ratings BreakdownLatest PAVM, MODD, ECOR, and DXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.503/17/2025DXRDaxorAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.75 ➝ $25.003/13/2025ECORelectroCoreLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $26.003/13/2025ECORelectroCoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxor$2.13M17.57N/AN/AN/A∞ECORelectroCore$26.46M1.39N/AN/A$1.24 per share4.01MODDModular MedicalN/AN/AN/AN/A$0.25 per shareN/APAVMPAVmed$1.99M5.55N/AN/A($3.35) per share-0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AECORelectroCore-$18.83M-$1.56N/AN/AN/A-54.40%-154.45%-69.16%8/6/2025 (Estimated)MODDModular Medical-$17.47M-$0.53N/A∞N/AN/A-197.97%-162.31%6/20/2025 (Estimated)PAVMPAVmed-$64.18M$0.71N/AN/AN/A602.97%N/A-92.36%8/12/2025 (Estimated)Latest PAVM, MODD, ECOR, and DXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ECORelectroCore-$0.56-$0.47+$0.09-$0.47$6.93 million$6.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxor$0.030.39%N/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/AMODDModular MedicalN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AECORelectroCoreN/A2.121.87MODDModular MedicalN/A5.305.30PAVMPAVmedN/A0.060.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%ECORelectroCore26.74%MODDModular Medical27.47%PAVMPAVmed19.93%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.00%ECORelectroCore19.70%MODDModular Medical20.46%PAVMPAVmed7.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.98 millionNot OptionableECORelectroCore507.42 million5.35 millionNot OptionableMODDModular Medical2054.25 million32.35 millionNot OptionablePAVMPAVmed9017.09 million9.82 millionOptionablePAVM, MODD, ECOR, and DXR HeadlinesRecent News About These CompaniesEarnings call transcript: PAVmed’s Q1 2025 sees strong net income and strategic shiftsMay 16, 2025 | investing.comPAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comPAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial FortificationMay 16, 2025 | finance.yahoo.comPAVmed Inc. (PAVM) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comPAVmed Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | prnewswire.comPAVmed Q1 2025 Earnings PreviewMay 14, 2025 | msn.comLucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025April 30, 2025 | prnewswire.comPAVmed (PAVM) Upgraded to Buy: Here's What You Should KnowApril 28, 2025 | zacks.comPAVmed switches to new accounting firm post-acquisitionApril 27, 2025 | investing.comNCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERDApril 24, 2025 | prnewswire.comLucid Diagnostics Announces Closing of Public Offering of Common StockApril 11, 2025 | prnewswire.comLucid Diagnostics Shares Drop After $15M Public Offering PricedApril 10, 2025 | marketwatch.comLucid Diagnostics Announces Pricing of Public Offering of Common StockApril 9, 2025 | prnewswire.comLucid Diagnostics Announces Pricing of Public Offering of Common StockApril 9, 2025 | prnewswire.comLucid Diagnostics Announces Proposed Public Offering of Common StockApril 9, 2025 | prnewswire.comPAVmed files to sell 3.33M shares of common stock for holdersApril 8, 2025 | msn.comLucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceApril 3, 2025 | prnewswire.comEarnings call transcript: PAVmed Q4 2024 reports net income boostMarch 27, 2025 | uk.investing.comPAVmed reports Q4 adjusted EPS (6c) vs. ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNextracker’s Solar Surge: Will It Shatter Its All-Time High?By Thomas Hughes | May 18, 2025View Nextracker’s Solar Surge: Will It Shatter Its All-Time High?Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?By Leo Miller | May 16, 2025View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?By Chris Markoch | April 30, 2025View CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Gold’s Record Run in 2025: Here Are 3 Ways to Ride the SurgeBy Ryan Hasson | May 7, 2025View Gold’s Record Run in 2025: Here Are 3 Ways to Ride the SurgePAVM, MODD, ECOR, and DXR Company DescriptionsDaxor NASDAQ:DXR$7.74 -0.26 (-3.25%) As of 05/23/2025 03:51 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.electroCore NASDAQ:ECOR$4.97 -0.05 (-1.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.94 -0.02 (-0.50%) As of 05/23/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Modular Medical NASDAQ:MODD$0.85 +0.02 (+2.25%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.85 +0.00 (+0.14%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.PAVmed NASDAQ:PAVM$0.65 0.00 (-0.49%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.65 +0.00 (+0.03%) As of 05/23/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
